The Challenge of Metastatic Colorectal Cancer

摘要: Colorectal cancer (CRC) is a very common disease with high rate of mortality around the world, representing second most frequent cause cancer-related death. As majority patients are diagnosed advanced subsequent low five-year survival (10%), it imperative to develop new strategies treat this challenging patient population. Traditionally, received successive lines chemotherapy and discontinued treatment or switched different one in event progression. But despite therapeutic advances achieved combination regimens, particularly FOLFOX FOLFIRI, considerable research has been necessary further optimize for metastatic colorectal (mCRC). However, progress over recent years. The relevant relates approval several effective drugs, such as monoclonal antibodies, which have greatly improved outcomes disease. last agent approved panitumumab, designed target epidermal growth factor receptor molecular pathway involved appearance spread cancer.